VIP regulation of immune responses expanded beyond Th1/Treg balance to include Th17 cell modulation, with VIP suppressing pathogenic Th17 differentiation — broadening its anti-autoimmune therapeutic potential.
Key findingVIP's immunomodulatory spectrum expanded to include Th17 cell regulation: suppressing pathogenic IL-17 producing cells in addition to its established
What the researchers found
VIP's immunomodulatory spectrum expanded to include Th17 cell regulation: suppressing pathogenic IL-17 producing cells in addition to its established Th1 suppression and Treg promotion — comprehensive anti-autoimmune peptide with Th1/Th17/Treg triple regulation.
Why it matters
Relevant for neuropeptides, immune-function, inflammation.
How the study worked
review study.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity.
Annals of the New York Academy of Sciences, 1144, 83-9
Citation
Yadav, Mahesh; Goetzl, Edward J. (2008). Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity.. Annals of the New York Academy of Sciences, 1144, 83-9. https://doi.org/10.1196/annals.1418.020